To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
Within the Institute, the "Funding Research and Technology Transfer" team is at your disposal to identify the scientists and the skills you need to set up a joint project, to define the terms of a collaboration contract or study.
Whether you are an academic, a SME or an industrialist, our team informs and advices you about the possibilities of consortium assembly, technology transfer, patent licensing or use of our platforms.
The team is also at the disposal of the researchers of the institute to accompany them in achieving their valorization objectives.
Europe | European ＆ international partnerships | Diseases | Diagnosis and innovative treatment
DEcompensated CIrrhoSIs: identification of new cOmbiNatorial therapies based on systems approaches
The DECISION consortium aims to identify and optimize new combinatorial therapies to prevent high mortality in patients with decompensated cirrhosis.
Mortality from cirrhosis is primarily associated with decompensation of cirrhosis (development of ascites, hepatic encephalopathy, gastrointestinal bleeding, and progression to acute-on-chronic liver failure (ACLF). Despite multiple treatments, mortality of patients with decompensated cirrhosis remains high. The EU-funded DECISION project aims to understand the pathophysiology of cirrhosis decompensation leading to ACLF or death and to decrease patient mortality. The project will investigate the pathophysiology of cirrhosis decompensation by integrating the results of high-throughput multi-comic profiling with comprehensive clinical data from 2,200 fully characterized patients with available standardized biological samples. DECISION will help identify novel combinatorial therapies to prevent high mortality in patients with decompensating cirrhosis. Finally, researchers will optimize these therapies in new animal models and then test the best combination in high-risk patients in a phase II clinical trial.
Contact Joliot Institute: Christophe Junot (firstname.lastname@example.org)
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.